(GERN) Geron - Overview
Exchange: NASDAQ •
Country: United States •
Currency: USD •
Type: Common Stock •
ISIN: US3741631036
Stock: Cancer Drugs, Therapeutics
Total Rating 19
Risk 32
Buy Signal -0.87
| Risk 5d forecast | |
|---|---|
| Volatility | 68.2% |
| Relative Tail Risk | -9.93% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 0.13 |
| Alpha | -23.98 |
| Character TTM | |
|---|---|
| Beta | 0.636 |
| Beta Downside | 2.242 |
| Drawdowns 3y | |
|---|---|
| Max DD | 78.98% |
| CAGR/Max DD | -0.16 |
EPS (Earnings per Share)
Revenue
Risks
Technicals:
choppy
Description: GERN Geron March 05, 2026
Geron Corporation (NASDAQ: GERN) is a commercial-stage biopharmaceutical company specializing in oncology therapeutics.
Their primary product is RYTELO, a telomerase inhibitor. This drug treats myelodysplastic syndromes (MDS) in adult patients who have low- to intermediate-1 risk and transfusion-dependent anemia. MDS is a group of cancers where immature blood cells in the bone marrow do not mature or become healthy blood cells.
The company, founded in 1990, operates from Foster City, California. The biotechnology sector is characterized by extensive research and development cycles and significant regulatory hurdles for product approval.
For more in-depth analysis of Gerons financials and market position, consider exploring ValueRay.
Headlines to watch out for
- RYTELO sales performance drives revenue growth
- Myelodysplastic syndromes market competition impacts share
- Clinical trial results for pipeline candidates affect valuation
- Regulatory approvals for new indications expand market
- Manufacturing costs and supply chain efficiency influence profitability
Piotroski VR‑10 (Strict, 0-10) 1.5
| Net Income: -85.8m TTM > 0 and > 6% of Revenue |
| FCF/TA: -0.19 > 0.02 and ΔFCF/TA 17.46 > 1.0 |
| NWC/Revenue: 222.3% < 20% (prev 523.0%; Δ -300.7% < -1%) |
| CFO/TA -0.19 > 3% & CFO -111.0m > Net Income -85.8m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 4.66 > 1.5 & < 3 |
| Outstanding Shares: last quarter (667.2m) vs 12m ago 3.27% < -2% |
| Gross Margin: 85.96% > 18% (prev 0.98%; Δ 8.50k% > 0.5%) |
| Asset Turnover: 31.59% > 50% (prev 12.97%; Δ 18.62% > 0%) |
| Interest Coverage Ratio: -1.63 > 6 (EBITDA TTM -52.1m / Interest Expense TTM 32.7m) |
Altman Z'' -12.17
| A: 0.72 (Total Current Assets 520.3m - Total Current Liabilities 111.5m) / Total Assets 570.5m |
| B: -3.25 (Retained Earnings -1.86b / Total Assets 570.5m) |
| C: -0.09 (EBIT TTM -53.1m / Avg Total Assets 582.2m) |
| D: -5.38 (Book Value of Equity -1.85b / Total Liabilities 344.7m) |
| Altman-Z'' Score: -12.17 = D |
Beneish M -2.62
| DSRI: 0.42 (Receivables 39.2m/38.8m, Revenue 183.9m/77.0m) |
| GMI: 1.14 (GM 85.96% / 98.01%) |
| AQI: 0.52 (AQ_t 0.09 / AQ_t-1 0.17) |
| SGI: 2.39 (Revenue 183.9m / 77.0m) |
| TATA: 0.04 (NI -85.8m - CFO -111.0m) / TA 570.5m) |
| Beneish M-Score: -2.62 (Cap -4..+1) = A |
What is the price of GERN shares?
As of March 20, 2026, the stock is trading at USD 1.55 with a total of 22,164,212 shares traded.
Over the past week, the price has changed by -3.13%, over one month by -19.27%, over three months by +16.54% and over the past year by -8.82%.
Over the past week, the price has changed by -3.13%, over one month by -19.27%, over three months by +16.54% and over the past year by -8.82%.
Is GERN a buy, sell or hold?
Geron has received a consensus analysts rating of 4.11.
Therefore, it is recommended to buy GERN.
- StrongBuy: 4
- Buy: 2
- Hold: 3
- Sell: 0
- StrongSell: 0
What are the forecasts/targets for the GERN price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 3.4 | 119.4% |
| Analysts Target Price | 3.4 | 119.4% |
GERN Fundamental Data Overview March 18, 2026
P/S = 5.7477
P/B = 4.4807
P/EG = -2.38
Revenue TTM = 183.9m USD
EBIT TTM = -53.1m USD
EBITDA TTM = -52.1m USD
Long Term Debt = 119.5m USD (from longTermDebt, last quarter)
Short Term Debt = 19.4m USD (from shortTermDebt, last quarter)
Debt = 251.6m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 172.1m USD (from netDebt column, last quarter)
Enterprise Value = 948.7m USD (1.06b + Debt 251.6m - CCE 359.8m)
Interest Coverage Ratio = -1.63 (Ebit TTM -53.1m / Interest Expense TTM 32.7m)
EV/FCF = -8.54x (Enterprise Value 948.7m / FCF TTM -111.1m)
FCF Yield = -11.71% (FCF TTM -111.1m / Enterprise Value 948.7m)
FCF Margin = -60.43% (FCF TTM -111.1m / Revenue TTM 183.9m)
Net Margin = -46.65% (Net Income TTM -85.8m / Revenue TTM 183.9m)
Gross Margin = 85.96% ((Revenue TTM 183.9m - Cost of Revenue TTM 25.8m) / Revenue TTM)
Gross Margin QoQ = none% (prev 53.18%)
Tobins Q-Ratio = 1.66 (Enterprise Value 948.7m / Total Assets 570.5m)
Interest Expense / Debt = 2.90% (Interest Expense 7.30m / Debt 251.6m)
Taxrate = 21.0% (US default 21%)
NOPAT = -42.0m (EBIT -53.1m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 4.66 (Total Current Assets 520.3m / Total Current Liabilities 111.5m)
Debt / Equity = 1.11 (Debt 251.6m / totalStockholderEquity, last quarter 225.9m)
Debt / EBITDA = -3.30 (negative EBITDA) (Net Debt 172.1m / EBITDA -52.1m)
Debt / FCF = -1.55 (negative FCF - burning cash) (Net Debt 172.1m / FCF TTM -111.1m)
Total Stockholder Equity = 250.6m (last 4 quarters mean from totalStockholderEquity)
RoA = -14.74% (Net Income -85.8m / Total Assets 570.5m)
RoE = -34.23% (Net Income TTM -85.8m / Total Stockholder Equity 250.6m)
RoCE = -14.35% (EBIT -53.1m / Capital Employed (Equity 250.6m + L.T.Debt 119.5m))
RoIC = -11.35% (negative operating profit) (NOPAT -42.0m / Invested Capital 369.7m)
WACC = 7.11% (E(1.06b)/V(1.31b) * Re(8.26%) + D(251.6m)/V(1.31b) * Rd(2.90%) * (1-Tc(0.21)))
Discount Rate = 8.26% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 5.89%
[DCF] Fair Price = unknown (Cash Flow -111.1m)
EPS Correlation: 79.18 | EPS CAGR: 53.04% | SUE: 0.54 | # QB: 0
Revenue Correlation: 84.34 | Revenue CAGR: 391.0% | SUE: -0.44 | # QB: 0
EPS next Quarter (2026-06-30): EPS=-0.01 | Chg7d=-0.005 | Chg30d=-0.005 | Revisions Net=+0 | Analysts=1
EPS current Year (2026-12-31): EPS=-0.02 | Chg7d=+0.005 | Chg30d=+0.005 | Revisions Net=+0 | Growth EPS=+80.6% | Growth Revenue=+24.7%
EPS next Year (2027-12-31): EPS=0.08 | Chg7d=-0.015 | Chg30d=-0.015 | Revisions Net=-1 | Growth EPS=+500.0% | Growth Revenue=+44.1%
P/B = 4.4807
P/EG = -2.38
Revenue TTM = 183.9m USD
EBIT TTM = -53.1m USD
EBITDA TTM = -52.1m USD
Long Term Debt = 119.5m USD (from longTermDebt, last quarter)
Short Term Debt = 19.4m USD (from shortTermDebt, last quarter)
Debt = 251.6m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 172.1m USD (from netDebt column, last quarter)
Enterprise Value = 948.7m USD (1.06b + Debt 251.6m - CCE 359.8m)
Interest Coverage Ratio = -1.63 (Ebit TTM -53.1m / Interest Expense TTM 32.7m)
EV/FCF = -8.54x (Enterprise Value 948.7m / FCF TTM -111.1m)
FCF Yield = -11.71% (FCF TTM -111.1m / Enterprise Value 948.7m)
FCF Margin = -60.43% (FCF TTM -111.1m / Revenue TTM 183.9m)
Net Margin = -46.65% (Net Income TTM -85.8m / Revenue TTM 183.9m)
Gross Margin = 85.96% ((Revenue TTM 183.9m - Cost of Revenue TTM 25.8m) / Revenue TTM)
Gross Margin QoQ = none% (prev 53.18%)
Tobins Q-Ratio = 1.66 (Enterprise Value 948.7m / Total Assets 570.5m)
Interest Expense / Debt = 2.90% (Interest Expense 7.30m / Debt 251.6m)
Taxrate = 21.0% (US default 21%)
NOPAT = -42.0m (EBIT -53.1m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 4.66 (Total Current Assets 520.3m / Total Current Liabilities 111.5m)
Debt / Equity = 1.11 (Debt 251.6m / totalStockholderEquity, last quarter 225.9m)
Debt / EBITDA = -3.30 (negative EBITDA) (Net Debt 172.1m / EBITDA -52.1m)
Debt / FCF = -1.55 (negative FCF - burning cash) (Net Debt 172.1m / FCF TTM -111.1m)
Total Stockholder Equity = 250.6m (last 4 quarters mean from totalStockholderEquity)
RoA = -14.74% (Net Income -85.8m / Total Assets 570.5m)
RoE = -34.23% (Net Income TTM -85.8m / Total Stockholder Equity 250.6m)
RoCE = -14.35% (EBIT -53.1m / Capital Employed (Equity 250.6m + L.T.Debt 119.5m))
RoIC = -11.35% (negative operating profit) (NOPAT -42.0m / Invested Capital 369.7m)
WACC = 7.11% (E(1.06b)/V(1.31b) * Re(8.26%) + D(251.6m)/V(1.31b) * Rd(2.90%) * (1-Tc(0.21)))
Discount Rate = 8.26% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 5.89%
[DCF] Fair Price = unknown (Cash Flow -111.1m)
EPS Correlation: 79.18 | EPS CAGR: 53.04% | SUE: 0.54 | # QB: 0
Revenue Correlation: 84.34 | Revenue CAGR: 391.0% | SUE: -0.44 | # QB: 0
EPS next Quarter (2026-06-30): EPS=-0.01 | Chg7d=-0.005 | Chg30d=-0.005 | Revisions Net=+0 | Analysts=1
EPS current Year (2026-12-31): EPS=-0.02 | Chg7d=+0.005 | Chg30d=+0.005 | Revisions Net=+0 | Growth EPS=+80.6% | Growth Revenue=+24.7%
EPS next Year (2027-12-31): EPS=0.08 | Chg7d=-0.015 | Chg30d=-0.015 | Revisions Net=-1 | Growth EPS=+500.0% | Growth Revenue=+44.1%